Navigation Links
Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
Date:10/31/2013

n existing products in all regions within our Generics segment, including products launched in the prior year.

Earnings from operations were $339.8 million for the three months ended September 30, 2013, compared to $334.7 million for the comparable prior year period. Adjusted earnings from operations, as further defined below, for the three months ended September 30, 2013 were $461.6 million as compared to adjusted earnings from operations of $512.6 million in the comparable prior year period. This decrease was driven by lower gross profit in the current year, as discussed above, and higher selling, general and administrative costs ("SG&A") and research and development costs ("R&D"). The increase in SG&A in the current quarter includes a fair value adjustment to increase the contingent consideration liability related to the Company's respiratory program by approximately $15 million and increased marketing costs incurred within the Specialty segment. R&D increased primarily due to expenditures related to the development of Mylan's respiratory and biologics programs. Additionally, during the current quarter, the Company recorded a $10.2 million gain, net, for litigation settlements principally related to recoveries of lost profits in patent-infringement matters totaling approximately $20 million, including recoveries related to product launches.

Interest expense for the three months ended September 30, 2013 totaled $74.0 million, compared to $76.1 million for the comparable prior year period. Adjusted interest expense, as further defined below, for the three months ended September 30, 2013 was $56.3 million as compared to adjusted interest expense of $61.0 million in the comparable prior year period. The decrease was the result of a lower effective interest rate in the current quarter due to refinancing transactions undertaken in previous periods.

Other (expense) income, net, was expense of $70.6 million in the current quarter c
'/>"/>

SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23

Related medicine technology :

1. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
2. Mylan to Speak at the Morgan Stanley Global Healthcare Unplugged Conference
3. Mylan to Speak at the Bank of America Merrill Lynch Global Healthcare Conference
4. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
5. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
6. Mylan Confirms Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
7. Mylan Reports a 13% Increase in Second Quarter 2013 Adjusted Diluted EPS to $0.68
8. Third Circuit Rules in Mylans Favor Regarding Paroxetine Hydrochloride Extended-Release Tablets, Sending Mylans Breach of Contract Claim Against GSK to Trial
9. Mylan to Host Investor Day on Aug. 1, 2013 in New York City
10. Roger Graham Named President of Mylan Specialty
11. Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Spanien, September 2, 2014 /PRNewswire/ ... auf dem ESC-Kongress 2014 präsentierte GARFIELD-AF-Register ... und Behandlungsergebnisse von schlaganfallgefährdeten Patienten in ... Die Daten der ... einer innovativen und unabhängigen Forschungsinitiative zur ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
(Date:9/2/2014)... , Sept. 2, 2014  Edison Nation Medical, ... partnership with the American Association for Respiratory Care ... respiratory care specialists. Edison Nation Medical, which brings ... business to commercialize their innovation ideas, will work ... of more than 50,000 respiratory therapists in bringing ...
Breaking Medicine Technology:Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 2Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 3Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 4Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 5Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 6Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 7Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 8Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 9Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 10Daten aus dem globalen Register zur Behandlung von Vorhofflimmern zeigen, dass antithrombotische Wirkstoffe zur Verhinderung von Schlaganfällen nicht optimal genutzt werden 11Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 2Edison Nation Medical and AARC Team Up To Promote Innovation in Respiratory Care 3
(Date:9/2/2014)... Sept. 2, 2014 (HealthDay News) -- Two new studies ... suggests that 6-year-olds who were breast-fed have a lower ... bottle-fed infants, while the other finds a similar trend ... the "many benefits of breast-feeding in the immediate newborn ... Hill Hospital in New York City. She was not ...
(Date:9/2/2014)... (HealthDay News) -- A leading group of oncologists has ... form of advanced breast cancer. HER2-negative breast ... target the HER2 protein, the American Society of Clinical ... Almost 80 percent of women with advanced breast ... releasing this guideline, our aim is to improve both ...
(Date:9/2/2014)... with less intensive (and expensive) practice patterns appear to ... patients unnecessary and excessive medical care, according to a ... "Growing concern about the costs and harms of medical ... avoid the provision of unnecessary care," said lead author ... Dartmouth Institute for Health Policy & Clinical Practice. ...
(Date:9/2/2014)... 02, 2014 When weather conditions are right, ... night, leaving behind a path of destruction. In fact, the ... average of 1,253 tornadoes per year. Rainbow International offers the ... a tornado strikes., , Select a safe ... in your home with no windows to stay during the ...
(Date:9/2/2014)... FL (PRWEB) September 02, 2014 Alliance ... targeting and multi-channel email marketing is pleased to announce ... market, Firearms & Freedom as well as ... properties represent more than one million concerned Americans who ... advertising. , “We are honored to continue providing ...
Breaking Medicine News(10 mins):Health News:More Evidence Breast-Feeding Lowers Child's Risk of Infections, Allergies 2Health News:New Guidelines for Treating Form of Advanced Breast Cancer 2Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Act Quickly in Case of Tornado: Rainbow International® Offers Tips on How to Be Prepared for a Tornado 2Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3
... 2010 Onconova Therapeutics, Inc. is presenting new data ... summarizing several studies with the company,s radioprotectant Ex-RAD at ... (RRS), September 25-29 in Maui, Hawaii. In vivo ... significant increase in survival versus placebo-treated groups in mice ...
... place Jan. 13-16, 2011 at the Wynn Las Vegas. ... (each morning), observing differences in technique from a variety ... Lectures and plenary sessions will cover topics as bladder, ... to treat patients with benign prostate cancer. , Also ...
... CA September 27, 2010 Hoag Memorial ... for patient-specific vaccine therapy to treat metastatic melanoma. ... that patient-specific vaccines can sometimes induce durable complete ... in one particular patient who participated in the ...
... puts children with a chronic lung condition caused by ... to a study from Johns Hopkins Children,s Center published ... The researchers say their findings should prompt pediatricians ... for signs of lung disease and to discuss the ...
... By Dennis Thompson HealthDay Reporter , FRIDAY, Sept. ... feared diseases on the planet, and the second leading cause ... is slowly conquering cancer, according to an assessment of cancer ... with the U.S. Centers for Disease Control and Prevention, the ...
... You,d think that people choosing to live near to outdoor ... BMI thanks to an increase in all that healthy outdoor ... Alberta study looking at the relationship between reasons for choosing ... that,s simply not the case. In fact researchers ...
Cached Medicine News:Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3Health News:Study shows patient-specific vaccines for metastatic melanoma may induce durable complete regression 2Health News:Daycare puts children with lung disease at risk for serious illness 2Health News:As Science Unlocks Secrets, Cancer Rates Fall 2Health News:As Science Unlocks Secrets, Cancer Rates Fall 3Health News:As Science Unlocks Secrets, Cancer Rates Fall 4Health News:Moving closer to outdoor recreation not a recipe for being more physically active 2
... Available in 6 popular colors ... Wide crescent shape to accommodate wheel ... exam. Strong, smooth and quiet elctro-mechanical ... top. 2 Position programmable memory Patient ...
Strong, 14 gauge steel construction for lasting quality. Locking wheels for use on carpet or tile flooring. Whisper quiet up/down movement. Easy cleaning deluxe laminated top. Three year warranty....
...
... construction for lifelong quality. Sealed hydraulic system ... movement. Soft, contoured cushions with heavy-duty upholstery ... slit lamp arm for easy, smooth, and ... lamp arm for easy access to children ...
Medicine Products: